Skip Navigation

This Article
Right arrow Full Text (PDF )
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (14)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Dimitry, E.S.
Right arrow Articles by Winston, R.M.L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dimitry, E.S.
Right arrow Articles by Winston, R.M.L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 6, No. 7, pp. 944-946, 1991
© 1991 European Society of Human Reproduction and Embryology

other

Beneficial effects of a 24 h delay in human chorionic gonadotrophin administration during in-vitro fertilization treatment cycles

E.S. Dimitry1, T. Oskarsson, J. Conaghan, R. Margara and R.M.L. Winston

Institute of Obstetrics and Gynaecology, Royal Postgraduate Medical School, Hammersmith Hospital London W12 OHS, UK

Correspondence: 1To whom correspondence should be addressed

We used a gonadotrophin-releasing hormone agonist (buserelin) and human menopausal gonadotrophin (HMG) for superovulation for in-vitro fertilization (IVF) in 143 patients. The patients were prospectively allocated to two balanced groups. In one group (47 patients) human chononic gonadotrophin (HCG) was given when the three largest follicles were ≥17 mm ni diameter, with consistent levels of plasma oestradiol (standard group). In the second group (96 patients), HCG injection was delayed by 24 h (delayed group). In the delayed group of patients, proportionately more had clinical pregnancies (52.1% versus 34.0%). These results suggest that IVF patients will benefit from delayed administration of HCG. The traditional criteria for HCG administration should be changed when buserelin is used.

Key words: delayed/HCG/IVF


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Endocr. Rev.Home page
N. S. Macklon, R. L. Stouffer, L. C. Giudice, and B. C. J. M. Fauser
The Science behind 25 Years of Ovarian Stimulation for in Vitro Fertilization
Endocr. Rev., April 1, 2006; 27(2): 170 - 207.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
E. M. Kolibianakis, C. Bourgain, E. G. Papanikolaou, M. Camus, H. Tournaye, A. C. Van Steirteghem, and P. Devroey
Prolongation of follicular phase by delaying hCG administration results in a higher incidence of endometrial advancement on the day of oocyte retrieval in GnRH antagonist cycles
Hum. Reprod., September 1, 2005; 20(9): 2453 - 2456.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
I. P. Kosmas, E. M. Kolibianakis, and P. Devroey
Association of estradiol levels on the day of hCG administration and pregnancy achievement in IVF: a systematic review
Hum. Reprod., November 1, 2004; 19(11): 2446 - 2453.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.